戴纳基 DYN 深 沪
已收盘 08-01 16:00:00 美东时间
10.05
+0.200
+2.03%
华盛通- 最 高10.313
- 今 开9.66
- 成交量 275.16万股
- 最 低 9.57
- 昨 收 9.85
- 总市值 11.46亿
- 52周最高 47.45
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 6.36
- 委 比 -23.74%
- 总股本 1.14亿
- 历史最高 47.45
- 量 比 0.97
- 振 幅 7.54%
- 历史最低 4.30
- 每 手 1
- 风险率 11.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Stifel Maintains Buy on Dyne Therapeutics, Lowers Price Target to $36
Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $66 to $36.
07-31 23:50
Dyne Therapeutics Q2 EPS $(0.97), Inline
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.97) per share which met the analyst consensus estimate. This is a 38.57 percent decrease over losses of $(0.70) per share from the same period last year.
07-29 04:29
Dyne Therapeutics GAAP EPS of -$0.97 misses by $0.01
Dyne Therapeutics press release (NASDAQ:DYN): Q2 GAAP EPS of -$0.97 misses by $0.01. Dyne expects that its existing cash, cash equivalents and marketable securities, including the net proceeds from th...
07-29 04:28
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Dyne Therapeutics reported Q2 2025 financial results, including $683.9M in cash, cash equivalents, and marketable securities. The company strengthened its balance sheet, extending its cash runway into Q3 2027. Clinical progress includes full enrollment in the DELIVER trial for DYNE-251 in DMD and ongoing enrollment for DYNE-101 in DM1, targeting potential U.S. Accelerated Approval submissions in 2026 and commercial launches in 2027. R&D expenses ...
07-28 20:10
Dynagas LNG Partners LP Declares Cash Distribution on Its Series A Preferred Units
Dynagas LNG Partners LP has announced a cash distribution of $0.5625 per Series A Preferred Unit, payable on August 12, 2025, to holders of record as of August 5, 2025. This is the 40th consecutive distribution since the units began trading. The Partnership has 3,000,000 Series A Preferred Units outstanding.
07-24 20:05
Dyne shares up after CEO buys stock
Dyne Therapeutics (NASDAQ:DYN) shares rose on Wednesday after the company's CEO, John Cox, bought 100,000 shares of the company. The stock is up 6%. The CEO bought 100,000 shares between a price range...
07-16 22:46
Satellos Bioscience names new chief medical officer
Satellos Bioscience (TSX:MSCL:CA) appointed Wildon Farwell, M.D., MPH, as chief medical officer. Dr. Farwell joins Satellos from Dyne Therapeutics (DYN), where he most recently served as CMO and med...
07-16 19:34
JP Morgan Maintains Neutral on Dyne Therapeutics, Lowers Price Target to $9
JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:DYN) with a Neutral and lowers the price target from $10 to $9.
07-16 00:19
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dyne Therapeutics announced the closing of its underwritten public offering, raising approximately $230 million by issuing 27,878,788 shares of common stock at $8.25 per share. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers. The company aims to develop therapeutics for genetically driven neuromuscular diseases, focusing on myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumera...
07-02 20:01
